Novartis antitrust lawyer sceptical of innovation review in pharma mergers

The head of Novartis’ antitrust legal team yesterday said innovation considerations while reviewing mergers in the pharmaceutical industry may be a solution in search of a problem.

Unlock unlimited access to all Global Competition Review content